Clinical trials: Melanoma of Skin
NSCLC, HNSCC
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of…
- Conditions
- NSCLC, HNSCC, Melanoma, Metastatic Cancer
- Trial name
- NCT05877430
- Testing
- CJRB-101, Pembrolizumab injection
- Where
- 4 sites in United States, South Korea
- Volunteers
- 160 people
- Sponsor
- CJ Bioscience, Inc.
Metastatic Melanoma
Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
This was a Phase 1, open-label, dose-escalation, single-center study in patients with histologically confirmed Stage III or IV melanoma and at least 3 metastatic cutaneous or subcutaneous lesions that were suitable and accessible…
- Trial name
- NCT01838200
- Testing
- Bacillus Calmette-Guérin (BCG) vaccine, Ipilimumab, Isoniazid
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma, Urothelial Carcinoma
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
The purpose of this study is to evaluate the switch from Nivolumab Intravenous (IV) infusions to Nivolumab Subcutaneous (SC) administration in participants with resected Stage IIIA/B/C/D or Stage IV melanoma or resected invasive…
- Trial name
- NCT05496192
- Testing
- Nivolumab/rHuPH20, Nivolumab
- Where
- 3 sites in Germany, Spain
- Sponsor
- Bristol-Myers Squibb
Squamous Cell Cancer, Squamous Cell Carcinoma
Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer
Randomized comparative trial of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice a day for 8 weeks vs 5% imiquimod cream in the treatment of biopsy proven squamous cell carcinomas of the skin in…
- Conditions
- Squamous Cell Cancer, Squamous Cell Carcinoma, Skin Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05932511
- Testing
- 30% ascorbic acid in DMSO
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Center for Biomedical Research, Inc.
Melanoma, Hodgkin Lymphoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors.
- Conditions
- Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
- Trial name
- NCT06521567
- Testing
- Cobolimab, Dostarlimab
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Unresectable Cutaneous Melanoma, Metastatic Cutaneous Melanoma
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.
- Trial name
- NCT05572463
- Testing
- Sintilimab + IBI110
- Where
- 13 sites in United States, Australia and 5 more
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Stage III Melanoma, Stage IV Melanoma
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
This is a Phase II single-arm, open-label, clinical trial evaluating the efficacy and safety of pazopanib in combination with paclitaxel as first line therapy for subjects with unresectable Stage III and Stage IV melanoma.
- Conditions
- Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma
- Trial name
- NCT01107665
- Testing
- Pazopanib and Paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Irvine
Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantly altered during treatment.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma
- Trial name
- NCT04490564
- Testing
- PD-L1 Kit
- Where
- 6 sites in Greece
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Pharmassist Ltd
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a person's white blood cells in the laboratory and reinfusing them may cause a stronger immune response…
- Trial name
- NCT00045357
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Refractory Melanoma
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma.
- Trial name
- NCT07288112
- Testing
- DOC1021, Tumor resection, pIFN (peginterferon alfa-2a)
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Diakonos Oncology Corporation
Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
This clinical phase II study is designed to investigate the efficacy of intratumorally administered L19IL2/L19TNF in patients with injectable lesions of BCC or cSCC.
- Trial name
- DUNCAN (NCT04362722)
- Testing
- L19IL2 +L19TNF
- Where
- 11 sites in Germany, Poland and 1 more
- Volunteers
- 40 people
- Sponsor
- Philogen S.p.A.
Metastatic Melanoma
A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
Thi pahse I, dose-escalation trial will determine the MTD, safety and the additional benefit achieved from adding SGI-110 to ipilimumab therapy in metastatic melanoma patients.
- Trial name
- NIBIT-M4 (NCT02608437)
- Testing
- SGI-110, Ipilimumab
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Italian Network for Tumor Biotherapy Foundation
Melanoma
Influence of a High-fiber Diet on the Microbiota and the Response to Immunotherapy in Patients Treated for Melanoma.
The underlying hypothesis of the study is that melanoma patients treated with immunotherapy, whether in an adjuvant or curative setting, who consume more fiber would respond better to immunotherapy: either no recurrence in the…
- Trial name
- FIBIOME (NCT07437300)
- Volunteers
- 60 people
- Sponsor
- University Hospital, Grenoble
Melanoma (Skin), Metastatic Cancer
Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00020839
- Testing
- temozolomide, radiation therapy
- Where
- 33 sites in Austria, Belgium and 9 more
- Volunteers
- 23 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-Small Cell Lung Cancer, Melanoma (Skin Cancer)
Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
The objective of this prospective multicenter study is to evaluate whether the analysis of immunological biomarkers present in circulating extracellular vesicles is associated with the response to anti-PD-1/PD-L1 treatments in…
- Trial name
- EVpredict (NCT07376512)
- Where
- 5 sites in France
- Volunteers
- 378 people
- Sponsor
- Centre Georges Francois Leclerc
Melanoma (Skin)
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells.Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00002767
- Testing
- Detox-B adjuvant, recombinant interferon alfa
- Where
- 27 sites in United States
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Melanoma
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
The purpose of this research study is to see if the combination of HSPPC-96 and ipilimumab is safe and effective in the treatment of advanced melanoma.
- Trial name
- NCT02452281
- Testing
- ipilimumab, HSPPC-96
- Where
- United States
- Sponsor
- Rabih Said
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
This study will evaluate the safety and tolerability of IL-2 when given in combination with pembrolizumab to patients with advanced melanoma. Aldesleukin may stimulate white blood cells to melanoma cells.
- Conditions
- Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma
- Trial name
- NCT02748564
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma (Skin)
Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01005537
- Testing
- aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.